BRPI0812384A2 - Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 - Google Patents

Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21

Info

Publication number
BRPI0812384A2
BRPI0812384A2 BRPI0812384-5A2A BRPI0812384A BRPI0812384A2 BR PI0812384 A2 BRPI0812384 A2 BR PI0812384A2 BR PI0812384 A BRPI0812384 A BR PI0812384A BR PI0812384 A2 BRPI0812384 A2 BR PI0812384A2
Authority
BR
Brazil
Prior art keywords
treatment
fgf21
diagnostic
methods associated
disease
Prior art date
Application number
BRPI0812384-5A2A
Other languages
English (en)
Inventor
Cheng Liu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0812384A2 publication Critical patent/BRPI0812384A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0812384-5A2A 2007-05-22 2008-05-20 Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 BRPI0812384A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93951207P 2007-05-22 2007-05-22
PCT/US2008/006481 WO2008153705A2 (en) 2007-05-22 2008-05-20 Methods of treating, diagnosing and detecting fgf21-associated disorders

Publications (1)

Publication Number Publication Date
BRPI0812384A2 true BRPI0812384A2 (pt) 2014-12-02

Family

ID=39739850

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812384-5A2A BRPI0812384A2 (pt) 2007-05-22 2008-05-20 Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21

Country Status (11)

Country Link
US (1) US20110002845A1 (pt)
EP (1) EP2152737A2 (pt)
JP (1) JP2010529954A (pt)
KR (1) KR20100017169A (pt)
CN (1) CN101679501A (pt)
AU (1) AU2008262450A1 (pt)
BR (1) BRPI0812384A2 (pt)
CA (1) CA2687746A1 (pt)
EA (1) EA200901550A1 (pt)
MX (1) MX2009012625A (pt)
WO (1) WO2008153705A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
SG193860A1 (en) 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
NZ592009A (en) 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
WO2010139741A1 (en) * 2009-06-04 2010-12-09 Novartis Ag Fgf-21 for treating cancers
JP2012530493A (ja) 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
CA2777717C (en) * 2009-10-15 2021-05-25 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
MX2012006397A (es) 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011127337A2 (en) * 2010-04-09 2011-10-13 Opko Curna Llc Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN102296110B (zh) * 2011-07-18 2016-08-10 西北农林科技大学 一种检测黄牛fgf21基因单核苷酸多态性的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3194441A1 (en) 2014-09-16 2017-07-26 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
US9955802B2 (en) 2015-04-08 2018-05-01 Fasteners For Retail, Inc. Divider with selectively securable track assembly
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CN107449715B (zh) * 2016-05-30 2021-01-22 康建胜 活细胞胞内代谢分析仪及其分析方法
CN110036029A (zh) 2016-11-17 2019-07-19 瑞泽恩制药公司 用抗angptl8抗体处理肥胖的方法
US20200000880A1 (en) 2017-02-01 2020-01-02 Children's Medical Center Corporation Fgf21 compositions for treatment or prevention of neovascularization of the eye and methods therefor
WO2018187418A1 (en) * 2017-04-04 2018-10-11 Genentech, Inc. Substrates recognized by fibroblast activation protein (fap) and methods of using the same
JP7066540B2 (ja) * 2018-06-14 2022-05-13 株式会社日立製作所 デジタルｐｃｒの測定方法および測定装置
CN110279847B (zh) * 2019-05-17 2023-04-14 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 Fgf21在制备促进超长随意皮瓣存活的药物中的应用
CN110257512A (zh) * 2019-05-20 2019-09-20 上海交通大学医学院 用于luminal型和HER2型乳腺癌诊断、治疗及预后的标志物和组合物
CN111420030B (zh) * 2020-05-12 2021-01-29 江南大学 Fgf21在制备用于治疗结直肠癌药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7368100A (en) * 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1628101A (en) * 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
CA2585822A1 (en) * 2000-06-02 2001-12-13 Genentech, Inc. Breast, rectal, colon and lung tumour marker pro19628 polypeptide and encoding nucleic acid
WO2004022723A2 (en) * 2002-09-09 2004-03-18 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2008522617A (ja) * 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
EP1846019A2 (en) * 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
JP2006246823A (ja) * 2005-03-11 2006-09-21 Kyoto Univ 造血因子としてのＦｇｆ２１の使用

Also Published As

Publication number Publication date
KR20100017169A (ko) 2010-02-16
EP2152737A2 (en) 2010-02-17
MX2009012625A (es) 2009-12-07
US20110002845A1 (en) 2011-01-06
WO2008153705A3 (en) 2009-03-05
WO2008153705A2 (en) 2008-12-18
CN101679501A (zh) 2010-03-24
JP2010529954A (ja) 2010-09-02
EA200901550A1 (ru) 2010-10-29
CA2687746A1 (en) 2008-12-18
AU2008262450A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
BRPI0917567A2 (pt) tratamento de doença respiratória
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
BRPI0814889A2 (pt) tratamento com ligantes alfa7-seletivos.
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
FR2921499B1 (fr) Structure orientable de type catheter ou endoscope
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
BRPI0722004A2 (pt) Posto de saúde.
BRPI0807896A2 (pt) Fórceps bipolares não-aderentes.
BRPI0922322A2 (pt) endoscópio com uma porção curvada
BRPI0822633A2 (pt) Desinfetante, e, método de esterilização.
HUE071237T2 (hu) Fabry-kór kezelési lehetõségei
BRPI0816794A2 (pt) Tratamento pós-colheita.
BRPI0923409A2 (pt) cabeça de escova de dentes, e, escova de dentes.
BRPI0815889A2 (pt) Análise do perfil de glicosilação.
FR2917962B1 (fr) Electrocardiographe ambulatoire evenementiel.
BRPI0822572A2 (pt) Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações
BRPI0820101A2 (pt) Combinação, e, aparelho que cobre a cabeça de estetoscópio
BRPI0822381A2 (pt) Agulha de coleta de sangue com sinalização
DE602007001361D1 (de) Sphinkterotom mit Zweifachkrümmung
SI2432798T1 (sl) Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postopki izdelave in uporaba pri zdravljenju bolezni
ATE494839T1 (de) Gewebeentnahme
FI20075181L (fi) Hammashoitokone, jossa on ohjelmoitavissa olevia toimintoja
IL199807A0 (en) Biometric diagnosis
DK1863899T3 (da) Hudbehandlingspræparater
BRPI0923652A2 (pt) diagnóstico e tratamento de câncer usando anticorpo anti-lgr7

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]